Therapeutic Monoclonal Antibodies Report 2008-2023

This report investigates the global market for therapeutic monoclonal antibodies. While the pharmaceutical industry as a whole is suffering from single digit growth, thinner pipelines than before and pressure from an ever-aggressive generics industry, the segment of monoclonal antibodies therapeutics is thriving and growing at a double-digit rate. Therapeutic Monoclonal Antibodies 2008-2023 shows how monoclonal antibodies are a leading product of biotechnology, being increasingly used in therapy. Currently, monoclonal antibodies are playing an important role in the treatment of cancer, autoimmune and inflammatory disorders. Therapeutic monoclonal antibodies boast one of the most active and promising pipelines in the pharmaceutical industry.

Ten years ago, there were only two monoclonal antibody drugs on the world market, now there are 21 FDA approved therapies - including eight blockbuster drugs. In 2007, the market was worth $21.9bn, but what will it be in 5 years time? This report will tell you and tell you today. Visiongain believes that some of the greatest opportunities ever available for biopharmaceutical companies are now there to be seized, with important sales, licensing agreements and collaborative partnerships from the present onwards in monoclonal antibodies and other biologicals.

Our new Therapeutic Monoclonal Antibodies 2008-2023 report examines the market for monoclonal antibodies critically, through comprehensive primary and secondary research. In addition to consultation with experts in industry - including full interview transcripts - this research involved a detailed study of relevant documents, industrial reports and current developments. Visiongain discusses the monoclonal antibody market in the context of the biotechnological platforms and therapeutic areas. Importantly, visiongain applied techniques such as financial forecasting and analysis of drivers and restraints. The result is a comprehensive market-based report with detailed analyses and informed opinion.

In particular, Therapeutic Monoclonal Antibodies 2008-2023 concentrates on the following essential aspects of the monoclonal antibodies sector:

• Technologies that drive the MAb sector
• Therapy areas that drive the MAb sector
• Sales forecasts of the global therapeutic MAb market from 2008-2023 - including those of principal market segments, both by disease area and technology
• Sales forecasts for leading products worldwide in this sector
• Sales forecasts for therapeutic MAb sales in leading national markets, including China and India
• Key industrial players in the therapeutic monoclonal antibody sector - both established and emerging - including partnerships
• Drivers and opportunities in the MAb sector
• Restraints and threats in the MAb sector
• Assessments of relevant business models, technological solutions and associated issues
• Coverage of future trends in MAbs, especially pipeline developments
• Insight from interviews with relevant experts

Why you should buy this report:

• To receive a comprehensive analysis of the prospects for the therapeutic monoclonal antibodies industry from 2008-2023, including sales forecasts, major growth areas and pipeline products
• To discover predicted revenues, growth rates and other key metrics in the therapeutic monoclonal antibodies market from 2008-2023, especially for leading brands
• To determine the forces that influence the therapeutic monoclonal antibodies market:
• Drivers and restraints on market
• Competition
• Strengths, weaknesses, opportunities and threats.
• To find out where the therapeutic monoclonal antibodies market is heading from 2008 onwards - both technologically and commercially